We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AtriCure (ATRC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AtriCure is a member of our Medical group, which includes 946 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AtriCure is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATRC's full-year earnings has moved 32.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ATRC has gained about 32.7% so far this year. At the same time, Medical stocks have gained an average of 7.7%. This means that AtriCure is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Ensign Group (ENSG - Free Report) . The stock is up 34.4% year-to-date.
For Ensign Group, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AtriCure belongs to the Medical - Products industry, a group that includes 83 individual stocks and currently sits at #182 in the Zacks Industry Rank. On average, this group has gained an average of 1.9% so far this year, meaning that ATRC is performing better in terms of year-to-date returns.
Ensign Group, however, belongs to the Medical - Nursing Homes industry. Currently, this 2-stock industry is ranked #23. The industry has moved +31.7% so far this year.
Investors interested in the Medical sector may want to keep a close eye on AtriCure and Ensign Group as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AtriCure (ATRC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AtriCure is a member of our Medical group, which includes 946 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AtriCure is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATRC's full-year earnings has moved 32.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ATRC has gained about 32.7% so far this year. At the same time, Medical stocks have gained an average of 7.7%. This means that AtriCure is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Ensign Group (ENSG - Free Report) . The stock is up 34.4% year-to-date.
For Ensign Group, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AtriCure belongs to the Medical - Products industry, a group that includes 83 individual stocks and currently sits at #182 in the Zacks Industry Rank. On average, this group has gained an average of 1.9% so far this year, meaning that ATRC is performing better in terms of year-to-date returns.
Ensign Group, however, belongs to the Medical - Nursing Homes industry. Currently, this 2-stock industry is ranked #23. The industry has moved +31.7% so far this year.
Investors interested in the Medical sector may want to keep a close eye on AtriCure and Ensign Group as they attempt to continue their solid performance.